Dexborneol
Acute Ischemic Stroke
Nanfang Hospital, Southern Medical UniversitySmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 67/ 100
- Competitive Position
- 65/ 100
Competitive context
106 Active assets in the Acute Ischemic Stroke cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Compound Edaravone Nanfang Hospital, Southern Medical University | Phase 4 | BBB |
3-N-BUTYLPHTHALIDE Nanfang Hospital, Southern Medical University | Phase 4 | BBB |
Tenecteplase Hackensack Meridian Health | Phase 4 | BBB |
Tirofiban Weifang Medical University | Phase 4 | BB |
Nicardipine Haseki Training and Research Hospital | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Dexborneol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →